European Institute of Oncology
195
83
93
39
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.6%
7 terminated/withdrawn out of 195 trials
84.8%
-1.7% vs industry average
10%
19 trials in Phase 3/4
0%
0 of 39 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (195)
Role of the Immune System in Preventing Laryngeal Cancer
Role: lead
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
Role: lead
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Role: lead
PIK3CA Mutational Status Assessment
Role: lead
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
Role: lead
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Role: lead
Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,
Role: lead
Robotic Nipple-Sparing Mastectomy Vs Conventional Open Technique
Role: lead
Predicting Toxicity in Elderly Patients With Head and Neck Cancer
Role: lead
Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
Role: collaborator
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Role: lead
Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma
Role: lead
Germline Genetic Testing of the TP53 Gene
Role: lead
Digital Solutions for bEtter cAre
Role: lead
Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer
Role: lead
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Role: lead
Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
Role: lead
Sexual Well-being of Women Undergoing Mastectomy and Reconstruction
Role: lead
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Role: lead
IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER
Role: lead